Predicting the Effect of Gonadotropin-Releasing Hormone (GnRH) Analogue Treatment on Uterine Leiomyomas Based on MR Imaging

Purpose: To test the hypothesis that the simple assessment of signal intensity on T2-weighted MR images is predictive of the effect of hormonal treatment with gonadotropin-releasing hormone (GnRH) analogue. Material and Methods: The correlation between T2-weighted MR imaging of uterine leiomyomas and histologic findings was evaluated using 85 leiomyomas from 62 females who underwent myomectomy or hysterectomy. We also correlated the pretreatment MR images features obtained in 110 women with 143 leiomyomas with the effect of GnRH analogue treatment. The size (length×width×depth) of the leiomyoma was evaluated before and at 6 months after treatment by ultrasound. Results: The proportion of leiomyoma cell fascicles and that of extracellular matrix affected signal intensities of uterine leiomyomas on T2-weighted MR images. The amount of extracellular matrix was predominant in hypointense leiomyomas on T2-weighted images, while diffuse intermediate signal leiomyomas were predominantly composed of leiomyoma cell fascicles. Marked degenerative changes were noted in leiomyomas with heterogenous hyperintensity. The homogeneously intermediate signal intensity leiomyomas showed significant size reduction after treatment (size ratio; posttreatment volume/pretreatment volume 0.29±0.11). The size ratio for the hypointense tumors was 0.82±0.14, and 0.82±0.18 for the heterogeneously hyperintense tumors. There was a significant difference in the response to treatment between the homogeneously intermediate signal intensity leiomyomas and the hypointense or heterogeneously hyperintense leiomyomas (bothp<0.01). Conclusion: Signal intensity on T2-weighted MR images depends on the amount of leiomyoma cell fascicles and extracellular matrix. Simple assessment of the MR signal intensity is useful in predicting the effect of GnRH analogue on uterine leiomyomas.

[1]  小口 治 Prediction of histopathologic features and proliferative activity of uterine leiomyoma by magnetic resonance imaging prior to GnRH analogue therapy : correlation between T2-weighted images and effect of GnRH analogue , 1998 .

[2]  Y. Yamashita,et al.  Hyperintense uterine leiomyoma at T2-weighted MR imaging: differentiation with dynamic enhanced MR imaging and clinical implications. , 1993, Radiology.

[3]  K. Sugimura,et al.  MR Detection of Degenerating Uterine Leiomyomas , 1993, Journal of computer assisted tomography.

[4]  H. Minaguchi,et al.  Treatment effects of GnRH agonist on the binding of estrogen and progesterone, and the histological findings of uterine leiomyomas. , 2010, Asia-Oceania journal of obstetrics and gynaecology.

[5]  H. Okamura,et al.  Calcium metabolism in premenopausal women treated by a Gn-RH agonist for uterine myoma. , 1990, Endocrinologia japonica.

[6]  P. Googe,et al.  Histopathological changes in leiomyomata treated with leuprolide acetate. , 1990, Fertility and sterility.

[7]  S. Mccarthy,et al.  Monitoring therapy with a gonadotropin-releasing hormone analog: utility of MR imaging. , 1990, Radiology.

[8]  A. Megibow,et al.  The value of MR imaging in distinguishing leiomyomas from other solid pelvic masses when sonography is indeterminate. , 1990, AJR. American journal of roentgenology.

[9]  E. Zerhouni,et al.  A Placebo-Controlled Trial of a Depot Gonadotropin-Releasing Hormone Analogue (Leuprolide) in the Treatment of Uterine Leiomyomata , 1989, Obstetrics and gynecology.

[10]  H. Hricak,et al.  Use of an agonistic analog of gonadotropin-releasing hormone (nafarelin) to treat leiomyomas: assessment by magnetic resonance imaging. , 1988, American journal of obstetrics and gynecology.

[11]  R. Barbieri,et al.  A randomized, double-blind trial of a gonadotropin releasing-hormone agonist (leuprolide) with or without medroxyprogesterone acetate in the treatment of leiomyomata uteri. , 1988, Fertility and sterility.

[12]  H. Judd,et al.  Treatment of Endometriosis With a Long‐Acting Gonadotropin‐Releasing Hormone Agonist , 1987, Obstetrics and gynecology.

[13]  H. Hricak,et al.  Uterine leiomyomas: correlation of MR, histopathologic findings, and symptoms. , 1986, Radiology.

[14]  J. Lee,et al.  The uterus: in vitro MR-anatomic correlation of normal and abnormal specimens. , 1985, Radiology.

[15]  J. Fitzsimmons,et al.  MR Imaging of Uterine Leiomyomas and Their Complications , 1985, Journal of computer assisted tomography.

[16]  M. Soules,et al.  Leiomyomas: steroid receptor content. Variation within normal menstrual cycles. , 1982, American journal of obstetrics and gynecology.

[17]  E. Wallach,et al.  Uterine leiomyomata: etiology, symptomatology, and management. , 1981, Fertility and sterility.

[18]  E. D. Rees,et al.  Estradiol and Progesterone Binding in Uterine Leiomyomata and in Normal Uterine Tissues , 1980, Obstetrics and gynecology.